Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Balaxi Pharma
Join Channel
Consolidated Standalone

Balaxi Pharma.

₹654.6 6 | 0.9%

WEBSITE BSE:0 NSE : 18 May, 12:42

Market Cap ₹723 Cr.

Stock P/E -129.3

P/B 3.6

Current Price ₹654.6

Book Value ₹ 179.4

Face Value 10

52W High ₹686.3

Dividend Yield 0%

52W Low ₹ 400

Edit Ratio

Balaxi Pharma. Research see more...

Overview Inc. Year: 1942Industry: Trading

Balaxi Pharmaceuticals Ltd, together with its subsidiaries, engages in the global wholesale distribution of prescription drugs, builder’s hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. It presents pharmaceutical products throughout numerous therapeutic regions that especially treats antibiotics, analgesic, anti malaria, and others. The employer also offers production equipment, electrical equipment, agricultural equipment, and others; and biscuits, wafers, toothpastes, ketchups, hand sanitizers, disinfectants, and other merchandise. The organization changed into formerly referred to as Balaxi Ventures Ltd and changed its name to Balaxi Pharmaceuticals Ltd in October 2020. Balaxi Pharmaceuticals Ltd changed into integrated in 1942 and is centred in Hyderabad, India.

Read More..

Balaxi Pharma. Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Balaxi Pharma. Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 70 62 89 83 86 87 81 66 55 61
Other Income 0 -0 4 3 4 -5 -0 -1 0 -0
Total Income 70 61 93 86 91 82 80 65 55 61
Total Expenditure 56 48 78 69 72 71 68 57 44 47
Operating Profit 14 13 15 17 19 11 13 8 11 14
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 1 0 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 -47 6 2
Profit Before Tax 14 13 15 17 19 11 11 -39 16 14
Provision for Tax 2 1 2 3 3 2 3 2 1 1
Profit After Tax 12 12 13 14 15 8 8 -41 14 14
Adjustments 0 0 0 -0 0 0 0 -0 0 0
Profit After Adjustments 12 12 13 14 15 8 8 -41 14 14
Adjusted Earnings Per Share 12.1 12.2 12.7 14.1 15.5 8.2 8 -40.4 14.1 13.3

Balaxi Pharma. Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 14 46 231 279 336 263
Other Income 1 1 2 5 3 -1
Total Income 14 46 234 284 339 261
Total Expenditure 12 37 189 229 279 216
Operating Profit 2 9 45 56 60 46
Interest 0 0 0 1 1 0
Depreciation 0 0 0 1 2 2
Exceptional Income / Expenses 0 0 0 0 0 -39
Profit Before Tax 2 9 44 55 57 2
Provision for Tax 0 3 6 7 11 7
Profit After Tax 2 6 38 48 46 -5
Adjustments 0 0 -1 1 6 0
Profit After Adjustments 2 6 37 48 52 -5
Adjusted Earnings Per Share 6.5 6.1 37.2 48.2 50.8 -5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 20% 94% 0% 0%
Operating Profit CAGR 7% 88% 0% 0%
PAT CAGR -4% 97% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 20% 3% 43% NA%
ROE Average 32% 56% 53% 53%
ROCE Average 37% 63% 63% 63%

Balaxi Pharma. Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 4 28 65 113 183
Minority's Interest 0 0 0 0 0
Borrowings 0 0 0 0 1
Other Non-Current Liabilities 0 0 0 0 3
Total Current Liabilities 3 8 35 63 53
Total Liabilities 6 36 100 176 240
Fixed Assets 0 0 2 29 41
Other Non-Current Assets 0 1 3 7 5
Total Current Assets 6 35 94 141 194
Total Assets 6 36 100 176 240

Balaxi Pharma. Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 2 0 4 2 7
Cash Flow from Operating Activities -2 -14 0 34 6
Cash Flow from Investing Activities -0 -0 -6 -28 -11
Cash Flow from Financing Activities 0 18 4 -0 26
Net Cash Inflow / Outflow -2 4 -2 6 21
Closing Cash & Cash Equivalent 0 4 2 7 28

Balaxi Pharma. Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 6.47 6.13 37.23 48.18 50.82
CEPS(Rs) 6.48 6.11 38.44 48.17 46.87
DPS(Rs) 0 0 0 0.5 0
Book NAV/Share(Rs) 11.58 27.75 64.98 113.16 169.51
Core EBITDA Margin(%) 11.46 18.09 18.45 18.19 17.07
EBIT Margin(%) 17.96 19.38 19.28 19.79 17.33
Pre Tax Margin(%) 17.94 19.27 19.16 19.51 16.92
PAT Margin (%) 14.46 13.38 16.49 17.06 13.66
Cash Profit Margin (%) 14.49 13.39 16.61 17.24 14.18
ROA(%) 32.19 29.01 56.23 34.52 22.09
ROE(%) 55.84 39.04 82.26 53.5 32.17
ROCE(%) 69.35 56.56 92.56 59.62 37.46
Receivable days 146.96 140.73 84 68.14 43.31
Inventory Days 0 6.66 11.4 73.37 110.51
Payable days 74.17 38.51 31.52 69.04 75.41
PER(x) 5.88 12.07 14.09 7.3 10.44
Price/Book(x) 3.28 2.67 8.07 3.11 3.13
Dividend Yield(%) 0 0 0 0.14 0
EV/Net Sales(x) 0.84 1.53 2.28 1.25 1.56
EV/Core EBITDA(x) 4.67 7.91 11.72 6.24 8.72
Net Sales Growth(%) 0 235.65 406.95 20.77 20.42
EBIT Growth(%) 0 262.13 404.51 23.93 5.46
PAT Growth(%) 0 210.47 524.83 24.96 -3.56
EPS Growth(%) 0 -5.22 507.5 29.41 5.48
Debt/Equity(x) 0 0 0.06 0.03 0.07
Current Ratio(x) 2.23 4.24 2.7 2.23 3.64
Quick Ratio(x) 2.23 4.14 2.31 0.67 1.67
Interest Cover(x) 1061.57 184.97 160.34 72.69 42.33
Total Debt/Mcap(x) 0 0 0.01 0.01 0.02

Balaxi Pharma. Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 72.86 72.86 72.86 72.86 72.69 71.57 71.22 71.22 71.22 66.86
FII 19.45 19.28 19 19 18.95 18.66 18.57 18.57 18.57 17.21
DII 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.02
Public 7.66 7.83 8.11 8.11 8.33 9.75 10.18 10.18 10.18 15.91
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 56%
  • Company is almost debt free.

Cons

  • Debtor days have increased from 69.04 to 75.41days.
  • Stock is trading at 3.6 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Balaxi Pharma. News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!